3 results
To assess the analgesic efficacy, safety, and tolerability of once daily orally administered cebranopadol in a total of 3 fixed doses (100 µg, 300 µg, and 600 µg cebranopadol) compared to placebo in subjects with moderate to severe chronic pain due…
Since coughing is the major symptom in BE, the objective of this trial is to evaluate the clinical efficacy of ICS/LABA treatment in subjects with BE on coughing. The primary outcome variables of interest is the Leicester cough questionnaire (LCQ),…
Primary • To evaluate the effects of cebranopadol and oxycodone on respiratory drive.Secondary• To evaluate the pupil response/ pupillometry following single oral doses of cebranopadol and oxycodone• To evaluate the effects of single oral doses of…